ArticleThe Lancet regional health. Western Pacific2024
Molecular and clinical epidemiology of carbapenem resistant
Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Predictive Performance of Sepsis Scoring Tools for In-Hospital Mortality Among Patients With Suspected Sepsis Presenting to the Colonial War Memorial Hospital Emergency Department, Fiji.Emergency medicine Australasia : EMA · 2026Observational
- Article
- Comparative evaluation of tigecycline susceptibility testing methods for carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii.Annals of clinical microbiology and antimicrobials · 2026Article
- Antimicrobial susceptibility trends of WHO critical Gram-negative pathogens in Fijian Hospitals, 2016-2021.JAC-antimicrobial resistance · 2026Article
- Analysis of clinical characteristics and whole-genome sequencing of carbapenem-resistant Acinetobacter baumannii isolates from pediatric patients in Guangxi, China.BMC microbiology · 2026Article
- High-Resolution Genomic Surveillance of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Distinct molecular characteristics and virulence profiles of carbapenem-resistantMicrobiology spectrum · 2025Article
- Establishment of a method for the rapid detection of carbapenem-resistant Pseudomonas aeruginosa based on bla_NDM with one-tube RPA-CRISPR/Cas12a visualization.Archives of microbiology · 2025Article
- Genomic diversity of clinically relevant bacterial pathogens from an acute care hospital in Suva, Fiji.JAC-antimicrobial resistance · 2025Article
- Diverse modes of ceftazidime/avibactam resistance acquisition in carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa from a Chinese intensive care unit.Annals of clinical microbiology and antimicrobials · 2025Article
- Unveiling the molecular epidemiology of Pseudomonas aeruginosa in lung infections among cystic fibrosis patients in the Brazilian Amazon.BMC microbiology · 2025Article
- Analysis of intrahospital and global dissemination and resistome dynamics of NDM-1-producing ST773JAC-antimicrobial resistance · 2025Article
- Establishing carbapenem resistant organism surveillance, prevention, and control in a middle-income country: implementation of a hospital-based program in Fiji.Antimicrobial resistance and infection control · 2025Article
- Phylogenomic analysis of OXA-23-positive and genetic context of rare NDM-1-producing carbapenem-resistantFrontiers in microbiology · 2025Article
- Economic Burden of Carbapenem-Resistant Organisms in Critically Ill Patients: A Multicenter, Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Complex Infection-Control Measures with Disinfectant Switch Help the Successful Early Control of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Environmental contamination with carbapenem resistantFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem resistant organisms (CROs) such as Methods: CROs isolated from 211 (77.3%) non-sterile (urinary catheters, urine, sputum, wound swab, and endotracheal tube) and 62 (22.7%) normally sterile (blood, cerebrospinal fluid, intravascular catheter, and aspirates) body sites of 272 patients treated at the three major hospitals in Fiji, the Colonial War Memorial Hospital (CWMH), Lautoka Hospital (LTKH), and Labasa Hospital (LBSH), and outer peripheral health centres around Fiji, were analysed. Clinical and demographic patient data such as age, sex, admission diagnosis, admission and discharge dates, patient outcomes, date of death, start and end date of meropenem and colistin treatment were reviewed. These CRO isolates comprised Findings: Of 272 patients, 140 (51.5%) were male, the median (range) age of patients was 45 (<1-89) years, 161 (59.2%) were I-Taukei, 104 (38.2%) Fijians of Indian descent, and 7 (2.6%) were from other ethnic backgrounds. 234 (86.0%) of these 272 patients, had their first positive CRO sample collected ≥72 h following admission and the remaining 38 (14.0%) were isolated within 72 h following admission. Of the 273 CROs, 146 (53.5%) were collected at the CWMH, 66 (24.2%) LTKH, and 61 (22.3%) LBSH, while 62 (22.7%) were isolated from normally sterile sites and 211 (77.3%) from sites that are not sterile. Of 273 isolates, 131 (48.0%) were CR Interpretation: We identified nosocomial transmission of distinct clones of CR Funding: This project was funded by the Otago Medical School Foundations Trust (Dean's Bequest Fund) and a Fiji National University seed grant. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.